Cybersecurity Risk with Medtronic MiniMed Insulin Pumps Prompts FDA Warning and Medtronic Recall
Register for the Medical Device Cybersecurity: Legacy Device Remediation, Compensating Controls, & End-of-Life Conference | September 26–27, 2019 | Attend in person or virtuallyYesterday FDA issued a safety communication alert to patients and healthcare providers about the Medtronic MiniMed insulin pump after the agency was made aware of potential cybersecurity vulnerabilities. The problem is that an unauthorized person could wirelessly connect to the insulin pump and then change its settings to either over-deliver insulin or stop insulin delivery, both of which can lead to adverse health consequences.
Medtronic cannot make updates to its MiniMed 508 and Paradigm insulin pump models that address the risks so the company is recalling several of the models and is giving patients alternative insulin pumps.
A full list of the recalled pumps is available on FDA’s website.
Related Articles
-
There is a risk that the delivery wire could break or separate during use, being left inside the patient’s bloodstream as a result.
-
The new pump allows patients to customize their diabetes management.
-
An analysis of the HVAD pump implant kit showed moisture had entered the center post of the pump causing corrosion and demagnetization of the internal magnets, which may cause the pump to rotate incorrectly.
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
